April 18th 2024
Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.
Metformin Could Reduce Long COVID Risk in People with Overweight or Obesity
June 9th 2023Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.
Lack of Timely Follow-up Care After Heart Failure Common in Type 2 Diabetes
June 7th 2023An analysis of Medicaid data from adults in Alabama suggests just more than 50% of patients fail to get ambulatory follow-up care within the recommended 14-day window following a first-time heart failure hospitalization.
SGLT2 Inhibitors Could Lower Risk of Recurrent Gout Flares in People with Diabetes
June 4th 2023A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.
Exploring the Impact of the Sotagliflozin Approval, with Deepak Bhatt, MD, MPH
May 27th 2023Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.
Diabetes Dialogue: What to Know about the iLet Bionic Pancreas
May 26th 2023As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.
Hour-Long Endoscopic Procedure Could Eliminate Need for Insulin in Type 2 Diabetes
May 4th 2023New research from a first-in-human study of a novel procedure involving electroporation of the superficial layer of the mucosa in the small intestine could help eliminate need for insulin in some people with type 2 diabetes.
Diabetes Dialogue: SURMOUNT-2 Reaction, Omnipod GO, and Verapamil for T1D
May 3rd 2023In this episode, hosts offer their reaction to topline data from the SURMOUNT-2 trial examining tirzepatide for weight management in T2D, the FDA's clearance of the Omnipod GO device, and results of the CLVer trial.
Clinical Data on Finerenone in Diabetic Kidney Disease
April 27th 2023Dr George Bakris reviews the clinical trial data for finerenone and provides insights on treatment selection, including the potential benefits of combination therapy with finerenone and SGLT2 inhibitors, in managing diabetic kidney disease.
Tirzepatide Achieves Mean Weight Loss of 15.7% in SURMOUNT-2 Trial
April 27th 2023Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.
Omnipod GO Receives FDA Clearance for People with Type 2 Diabetes
April 25th 2023Announced on April 25, 2023, the FDA's clearance of the Omnipod GO marks the first-of-its-kind for a basal-only insulin pod and is indicated for use as an insulin delivery device for people with type 2 diabetes aged 18 or older.